Cargando…

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

BACKGROUND: We aimed to evaluate the use of baricitinib, a Janus kinase (JAK) 1–2 inhibitor, for the treatment of patients admitted to hospital with COVID-19. METHODS: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multipl...

Descripción completa

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9333998/ https://www.ncbi.nlm.nih.gov/pubmed/35908569 http://dx.doi.org/10.1016/S0140-6736(22)01109-6

Ejemplares similares

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Publicado: (2021)

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Publicado: (2021)

Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Publicado: (2021)

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Publicado: (2022)

Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Publicado: (2020)

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Publicado: (2022)

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
Publicado: (2021)

Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
Publicado: (2023)

Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial
por: Karampitsakos, Theodoros, et al.
Publicado: (2023)

Baricitinib in hospitalised patients with COVID-19: A meta-analysis of randomised controlled trials
por: Selvaraj, Vijairam, et al.
Publicado: (2022)

BARICITINIB IN HOSPITALIZED PATIENTS WITH COVID-19: META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
por: SELVARAJ, VIJAIRAM, et al.
Publicado: (2022)

Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial
por: Hall, Frances C, et al.
Publicado: (2023)

Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial
por: Lopes, Renato D, et al.
Publicado: (2021)

Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial
por: Cohen, Jordana B, et al.
Publicado: (2021)

Use of covid-19 convalescent plasma to treat patients admitted to hospital for covid-19 with or without underlying immunodeficiency: open label, randomised clinical trial
por: Lacombe, Karine, et al.
Publicado: (2023)

The effects of combination-therapy of tocilizumab and baricitinib on the management of severe COVID-19 cases: a randomized open-label clinical trial
por: Dastan, Farzaneh, et al.
Publicado: (2023)

Comprehensive geriatric assessment for older adults admitted to hospital: meta-analysis of randomised controlled trials
por: Ellis, Graham, et al.
Publicado: (2011)

Baricitinib for the Management of SARS-CoV-2-Infected Patients: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
por: Manoharan, Sivananthan, et al.
Publicado: (2022)

P1594: BARICITINIB FOR STEROID-RESISTANT/RELAPSE IMMUNE THROMBOCYTOPENIA (BAITP): AN OPEN-LABEL, SINGLE-ARM, PHASE 2 TRIAL
por: Zhao, Peng, et al.
Publicado: (2023)

Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial
Publicado: (2023)

Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial
por: Hung, Ivan Fan-Ngai, et al.
Publicado: (2020)

Clinical impact of a routine, molecular, point-of-care, test-and-treat strategy for influenza in adults admitted to hospital (FluPOC): a multicentre, open-label, randomised controlled trial
por: Clark, Tristan W, et al.
Publicado: (2021)

Platform Randomised trial of INterventions against COVID-19 In older peoPLE (PRINCIPLE): protocol for a randomised, controlled, open-label, adaptive platform, trial of community treatment of COVID-19 syndromic illness in people at higher risk
por: Hayward, Gail, et al.
Publicado: (2021)

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
por: Kalil, Andre C., et al.
Publicado: (2020)

Randomised Ambulatory Management of Primary Pneumothorax (RAMPP): protocol of an open-label, randomised controlled trial
por: Hallifax, Rob, et al.
Publicado: (2019)

Baricitinib/propofol: Pancreatitis following off-label use: case report
Publicado: (2022)

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
por: Yu, Ly-Mee, et al.
Publicado: (2021)

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
Publicado: (2022)

Ambulatory management of primary spontaneous pneumothorax: an open-label, randomised controlled trial
por: Hallifax, Rob J, et al.
Publicado: (2020)

Spray on skin for diabetic foot ulcers: an open label randomised controlled trial
por: Manning, Laurens, et al.
Publicado: (2019)

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial
por: Ader, Florence, et al.
Publicado: (2022)

Awake prone positioning of hypoxaemic patients with COVID-19: protocol for a randomised controlled open-label superiority meta-trial
por: Tavernier, Elsa, et al.
Publicado: (2020)

Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial
por: Trøseid, Marius, et al.
Publicado: (2023)

Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden
por: Lundström, Erik, et al.
Publicado: (2020)

Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial
por: Wolfe, Cameron R, et al.
Publicado: (2022)

Current Use of Baricitinib in COVID-19 Treatment and Its Future: An Updated Literature Review
por: Dupuis, Derma, et al.
Publicado: (2022)

A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren’s syndrome patients
por: Bai, Wei, et al.
Publicado: (2023)

Baricitinib/lopinavir/ritonavir: Elevated transaminases and off-label use: case report
Publicado: (2020)

Baricitinib/ceftriaxone/metoclopramide: Extrapyramidal syndrome and off label use: case report
Publicado: (2021)

Gatifloxacin versus chloramphenicol for uncomplicated enteric fever: an open-label, randomised, controlled trial
por: Arjyal, Amit, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_484r32mgefm0errbhp1khabe6n